Integra sees Q3 reported revenue between $410 mln and $425 mln
Company expects Q3 adjusted EPS of $0.53 to $0.61
Integra updates 2026 reported revenue guidance to $1.654 bln-$1.695 bln due to FX impact
Overview
US medical technology firm's Q2 revenue rose 0.8%, a slight beat versus analyst expectations
Adjusted EPS for Q2 rose to $0.56, beating analyst expectations
Company reaffirmed full-year organic revenue growth and adjusted EPS guidance, lowered reported revenue outlook on FX
Result drivers
Specialty Surgery growth - Revenue growth in Specialty Surgery was driven by higher sales in Neurosurgery (notably Certas Plus, Bactiseal and CUSA) and Instruments
Tissue Reconstruction decline - Tissue Reconstruction revenue fell due to a mid-single digit decline in wound reconstruction, with Integra Skin impacted by a tough prior-year comparison
Supply reliability and manufacturing - Company cited improved supply reliability and initiation of production at its Braintree facility as supporting operational progress
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Integra Lifesciences Holdings Corp is $19.00, about 3.8% below its July 28 closing price of $19.76
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 4 three months ago
IART•
